And We Have Our First MEME Stock! $2.00 to $29.95.

Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg)

Guess we were bound to stumble across a meemster sooner or later! This is our 13th client idea to gain ten-fold, even if it was intraday and only for a few moments.

Adding American BriVision (ABVC) $2.00 to Watch List. Sometimes it pays to be early, the average daily volume back in April 2020 was 1,139 shares (not a misprint) and it’s traded 100 million shares today. What the?

Full Report: American BriVision (ABVC) $3.00 | Initiating Coverage

This was also on our Six Stocks We Expect Double List. $7.00 Price Potential at $3.30. With ABVC finally joining the party, all six companies doubled (peak value).

ABVC (ABVC) $3.30 to $29
Citius Pharma (CTXR) $1.02 to $4.56
Dicerna (DRNA) $20 to $40.14
Dyadic (DYAI) $5.91 to $10.35 (okay close)
Fortress Bio (FBIO) $2.70 to $6.10
Immunomedics (IMMU) $18.78 to $88 (acquired)

Bloomberg story:

Abhishek Vishnoi and Farah Elbahrawy, Mon, November 1, 2021, 10:21 AM

(Bloomberg) — A little known biotech company, ABVC BioPharma Inc., soared in U.S. premarket trading amid increasing chatter on trading social network StockTwits.

The Fremont, California-based firm’s shares jumped as much as 930% in premarket trading and the stock was up 254% at 10:17 a.m. in New York. More than 50 million shares had been traded in the stock by that time, compared to its 12-month daily average of around 660,000.

At the end of trading on Friday, the stock had a market capitalization of $68.1 million. That now stands at around $242 million.

The company has filed for $50 million mixed securities shelf on Friday. It announced restructuring of a joint venture last month and filed for patent applications for some medicines treating depression and attention-deficit hyperactivity disorder in September.

(Updates share move, adds trading volumes in second paragraph.)

Most Read from Bloomberg Businessweek

Client, see reports for full disclosure and disclaimer details.

Who’s better than us?